Clinical Trials in New York State

Showing 5421-5440 of 17,167 trials

The Lily Device Trial

NCT06786078

The goal of this clinical trial is to test if the Lily Device works to reduce chemotherapy induced hair loss in patients. It will also learn about the safety of the Lily Device. The main questions it aims to answer is: * Do patient preserve their hair using the Lily Device after 4 cycles of chemotherapy, when hair preservation is a Grade ≤1 graded by an independent healthcare professional on the Common Terminology Criteria for Adverse Events (CTCAE)? * What is the subject incidence of Grade 1 or above Adverse Device Events (ADE's)?

Chemotherapy Induced Alopecia

Luminate Medical, Inc.85 participantsStarted Dec 2024

Mullica Hill, New Jersey, United States • Vineland, New Jersey, United States • Binghamton, New York, United States +2 more locations

Active Not RecruitingPhase 369 miles

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.

Prostate Cancer

AstraZeneca1,035 participantsStarted Mar 2022

Yuma, Arizona, United States • Beverly Hills, California, United States • Cerritos, California, United States +214 more locations

The Lily Device Trial

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Find Trials by Condition in New York State

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

Novel Experimental COVID-19 Therapies Affecting Host Response

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Self-Assembling Matrix Forming Gel to Prevent Stricture Formation

A Randomized Controlled Trial of Leg Length Discrepancy Techniques

The OPBC-07/microNAC Study

SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

Intermediate-Size Expanded Access Protocol (EAP) for LP352

A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

Study of Nerve Repair and Reconstruction Associated With Major Extremity Trauma

The Gilenya Pregnancy Registry

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer